Entrada Therapeutics, Inc. (TRDA) compared with its closest peers (VNDA, RMTI, RNAC, FULC, TTRX). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | $318.12M | -2.4 |
| Rockwell Medical, Inc. (RMTI) | $315.76M | — |
| Cartesian Therapeutics, Inc. (RNAC) | $294.84M | -1.4 |
| Fulcrum Therapeutics, Inc. (FULC) | $291.46M | -9.6 |
| Turn Therapeutics Inc. (TTRX) | $282.84M | -33.6 |
| CAMP4 Therapeutics Corporation (CAMP) | $280.51M | -2.3 |
| Eledon Pharmaceuticals, Inc. (ELDN) | $279.13M | -2.9 |
| ALX Oncology Holdings Inc. (ALXO) | $273.84M | -0.6 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | $271.93M | -0.7 |
| Immuron Limited (IMRN) | $271.39M | — |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
TRDA overview · TRDA earnings · TRDA financials · TRDA KPIs · TRDA investor relations · TRDA ownership · TRDA filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.